Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by jopatcloon Jul 24, 2024 9:21am
65 Views
Post# 36145890

Good to see on Us2.ai

Good to see on Us2.aiInteresting 
Us2.ai - More studies and validation of our AI's performance for LV Volume and Function ...
great read ! great work ! Peder L. Myhre
. Nicola Gaibazzi

University Hospital of Parma
AI has the potential to reduce variability and analysis time.
While 3D echo is becoming more accurate, 2D imaging still dominates clinical care. This study evaluates agreement in measures of LV volume and function between human readers, Us2.ai and the 3D Heart Model.

Want to try out AI Echo .. contact us Us2.ai
Yoran M. Hummel - Nathan Simcox - Sabrina Fekecs

<< Previous
Bullboard Posts
Next >>